Montelukast and psychiatric disorders in children

Pharmacoepidemiology and Drug Safety

Volumn 18, Issue 9, 2009, Pages 858-864

  Wallerstedt, Susanna M ^a   Brunlöf, Gertrud ^a   Sundström, Anders ^b,c   Eriksson, Anna L ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b Medical Product Agency   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Adverse drug reaction; Children; Montelukast

Indexed keywords

ADRENALIN; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CETIRIZINE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; DESMOPRESSIN; FLUTICASONE; FORMOTEROL; HYDROCORTISONE; IPRATROPIUM BROMIDE; LORATADINE; MOMETASONE FUROATE; MONTELUKAST; SALBUTAMOL; SALMETEROL; TACROLIMUS; TERBUTALINE; THEOPHYLLINE;

AGGRESSIVENESS; AMNESIA; ANXIETY; APATHY; ARTICLE; ARTIFICIAL NEURAL NETWORK; ASTHMA; CHILD; DATA ANALYSIS; DATA BASE; DEPERSONALIZATION; DEPRESSION; DRUG INDUCED DISEASE; HALLUCINATION; HUMAN; HYPERACTIVITY; INSOMNIA; IRRITABILITY; MENTAL CONCENTRATION; MENTAL DISEASE; NIGHTMARE; PATHOLOGICAL CRYING; PERSONALITY DISORDER; PRIORITY JOURNAL; SIDE EFFECT; SLEEP DISORDER; SWEDEN;

ACETATES; ADOLESCENT; ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTI-ASTHMATIC AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; MALE; MENTAL DISORDERS; QUINOLINES; SWEDEN;

EID: 70450205246     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1794     Document Type: Article

References (13)

1. Edwards IR, Biriell C. Harmonisation in pharmacovigilance. Drug Saf 1994; 10: 93-102.
2. Impicciatore P, Choonara I, Clarkson A, et al. Incidence of adverse drug reactions in paediatric in/out-patients: a systematic review and meta-analysis of prospective studies. Br J Clin Pharmacol 2001; 52: 77-83. (Pubitemid 32862772)
3. Kimland E, Rane A, Ufer M, et al. Paediatric adverse drug reactions reported in Sweden from 1987 to 2001. Pharmacoepidemiol Drug Saf 2005; 14: 493-499.
4. Moore TJ, Weiss SR, Kaplan S, et al. Reported adverse drug events in infants and children under 2 years of age. Pediatrics 2002; 110: e53.
5. Meyboom RH. Adverse reaction to drugs in children, experiences with 'spontaneous monitoring' in The Netherlands. Bratisl Lek Listy 1991; 92: 554-559.
6. Medical Products Agency. Code of statutes. 2006.
7. Ducharme FM, Lasserson TJ, Cates CJ. Long-acting beta2- agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma. Cochrane Database Syst Rev 2006; CD003137.
8. Brunlof G, Tukukino C, Wallerstedt SM. Individual case safety reports in children in commonly used drug groups - signal detection. BMC Clin Pharmacol 2008; 8: 1.
9. Bate A, Lindquist M, Orre R, et al. Data-mining analyses of pharmacovigilance signals in relation to relevant comparison drugs. Eur J Clin Pharmacol 2002; 58: 483-490.
10. Bate A, Lindquist M, Edwards IR, et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol 1998; 54: 315-321. (Pubitemid 28328016)
11. Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf 2001; 10: 483-486. (Pubitemid 34100774)
12. Food and Drug Administration. Early Communication About an Ongoing Safety Review of Montelukast (Singulair). 2008.
13. European Medicines Agency. Meeting highlights from the Paediatric Committee 16-18 January 2008. 2008.